SAVA

Cassava Sciences, Inc. [SAVA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

SAVA Stock Summary

Top 10 Correlated Stocks

SAVA


In the News

10:16 20 Feb 2024 SAVA

3 small-cap biotechs with potential breakthroughs in 2024

There's a reason that many biotech investors prefer to stick with large-cap stocks. Investing in small-cap biotech stocks is not for risk-averse investors.

10:15 20 Feb 2024 SAVA

Is There Any Hope for Cassava Sciences Stock?

Cassava Sciences stock is down due to questions about some of its research. A lot is riding on its late-stage clinical trials to produce favorable data.

05:29 20 Feb 2024 SAVA

3 Biotech Stocks to Sell in January Before They Crash and Burn

The biotech segment is one of the most potent, boasting an impressive Compounding Annual Growth Rate (CAGR) of 13.96% until 2030. However, investing in biotech stocks also bears immense risk, as companies' performance relies heavily on drug approvals.

02:21 20 Feb 2024 SAVA

Portfolio Protection: 7 Risky Stocks to Drop Right Now

With investors moving back towards a “risk-on” stance in recent months, you may think that risky stocks could lead to outsized rewards this year. Yet while more favorable economic and market conditions could extend the current bull market (which started in October) well into 2024, an improving macro picture may not be enough for stocks that have large company-specific risks.

11:46 20 Feb 2024 SAVA

New SAVAW Warrants Are Trading After Cassava Sciences' Distribution

In the biotechnology sector, Cassava Sciences (NADSAQ: SAVA ) remains one of the top clinical-stage companies that investors are watching. Over the past one year, SAVA stock is down by less than 20% but up nearly 9% for the past six months.

06:06 20 Feb 2024 SAVA

Why Cassava Sciences Stock Zoomed 21% Higher This Week

The biotech has declared a fresh dividend. The payout is rather atypical -- it's in the form of common stock warrants.

02:02 20 Feb 2024 SAVA

Why Is Cassava Sciences (SAVA) Stock Up 15% Today?

Shares of pharmaceutical specialist Cassava Sciences (NASDAQ: SAVA ) soared earlier Tuesday before giving up most of the gains. Nevertheless, investor enthusiasm spiked over management's decision to issue a warrant distribution to support the ongoing Phase 3 clinical development of oral simulfilam, a promising therapeutic for patients of Alzheimer's disease.

07:31 20 Feb 2024 SAVA

Why Cassava Sciences Stock Soared Today

The biotech significantly modified its board of directors. Two of those incoming directors have extensive experience in the healthcare field; the other comes from the security sphere.

03:58 20 Feb 2024 SAVA

Alzheimer's Disease Drug Development: Another Lost Year

Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of Alzheimer's disease over the short term. Anavex's blarcamesine, Cyclo Therapeutics Trappsol Cyclo, Green Valley's GV-971, aromatherapy, and panax ginseng not only inhibit the formation of oxidants but scavenge them and reverse part of their damage.

03:15 20 Feb 2024 SAVA

Cassava Sciences: Likely Potential Opportunity From Phase 3 Readout Next Year

Cassava Sciences is a biotech company focused on developing treatments for Alzheimer's disease with its lead drug candidate, Simufilam. The company has faced allegations of data manipulation and misconduct, but no concrete evidence has been found to support these claims. The Phase 2 data for Simufilam showed potential cognitive benefits in patients with mild AD, but the results were inconsistent and had several limitations.

SAVA Financial details

Company Rating
Neutral
Market Cap
1B
Income
-91M
Revenue
-1.8K
Book val./share
3.69
Cash/share
3.39
Dividend
-
Dividend %
-
Employees
26
Optionable
No
Shortable
Yes
Earnings
26 Feb 2024
P/E
-11.07
Forward P/E
3.59
PEG
-0.65
P/S
-562087.03
P/B
6.5
P/C
6.63
P/FCF
-12.48
Quick Ratio
8.25
Current Ratio
8.62
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.19
EPS next Y
6.26
EPS next Q
1.58
EPS this Y
122.22%
EPS next Y
-385.84%
EPS next 5Y
-385.84%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-3.17%
-
-
-
-
SMA20
-7.69%
SMA50
14.29%
SMA100
33.33%
Inst Own
24.97%
Inst Trans
0.93%
ROA
-53%
ROE
-48%
ROC
-0.67%
Gross Margin
100%
Oper. Margin
5805333%
Profit Margin
5055389%
Payout
-
Shs Outstand
42.24M
Shs Float
38.25M
-
-
-
-
Target Price
-
52W Range
12.32-32.1
52W High
-29.72%
52W Low
+87.42%
RSI
40
Rel Volume
0.49
Avg Volume
1.01M
Volume
498.39K
Perf Week
-10.26%
Perf Month
-7.37%
Perf Quarter
5.89%
Perf Half Y
34.03%
-
-
-
-
Beta
-0.391
-
-
Volatility
0.71%, 1.03%
Prev Close
-5.31%
Price
22.49
Change
-8.54%

SAVA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.61-0.24-0.22-0.81-1.8
Operating cash flow per share
-0.45-0.14-0.21-0.77-1.93
Free cash flow per share
-0.45-0.15-0.21-1.33-2
Cash per share
1.851.333.585.925
Book value per share
1.841.273.536.445.66
Tangible book value per share
1.841.273.536.425.64
Share holders equity per share
1.841.273.536.445.66
Interest debt per share
00.010.010.01-0.09
Market cap
9.08M90.54M178.04M1.72B1.19B
Enterprise value
-10.73M67.55M84.82M1.49B986.69M
P/E ratio
-1.38-21.33-30.41-54.15-16.39
Price to sales ratio
0000-659.76K
POCF ratio
-1.9-36.02-33.08-57.03-15.32
PFCF ratio
-1.9-35.76-33.08-32.86-14.8
P/B Ratio
0.464.11.936.785.22
PTB ratio
0.464.11.936.785.22
EV to sales
0000-548.16K
Enterprise value over EBITDA
1.61-13.62-11.88-45.3-12.33
EV to operating cash flow
2.25-26.87-15.76-49.3-12.73
EV to free cash flow
2.25-26.68-15.76-28.41-12.3
Earnings yield
-0.72-0.05-0.03-0.02-0.06
Free cash flow yield
-0.53-0.03-0.03-0.03-0.07
Debt to equity
00000
Debt to assets
00000
Net debt to EBITDA
2.974.6413.067.12.51
Current ratio
39.2216.8350.419.5129.91
Interest coverage
000021.2
Income quality
0.730.540.850.931.02
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0000-6.66K
Research and developement to revenue
0000-37.8K
Intangibles to total assets
00000
Capex to operating cash flow
00.0100.740.03
Capex to revenue
00001.51K
Capex to depreciation
0-0.310-41.6-2.08
Stock based compensation to revenue
0000-1.15K
Graham number
5.042.644.2210.8215.15
ROIC
-0.33-0.2-0.06-0.13-0.33
Return on tangible assets
-0.33-0.18-0.06-0.12-0.31
Graham Net
1.811.253.55.64.82
Working capital
19.53M21.96M92.13M231.95M204.16M
Tangible asset value
19.63M22.1M92.2M252.84M226.92M
Net current asset value
19.53M21.96M91.89M231.62M203.93M
Invested capital
00000
Average receivables
00000
Average payables
359K373.5K682K4.02M5.57M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00961.0300
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
000.3800
Inventory turnover
00000
ROE
-0.33-0.19-0.06-0.13-0.32
Capex per share
000-0.56-0.07

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.48-0.43-0.52-0.63-0.61
Operating cash flow per share
-0.54-0.52-0.32-0.48-0.63
Free cash flow per share
-0.57-0.51-0.33-0.48-0.63
Cash per share
4.364.934.494.033.39
Book value per share
4.965.584.894.293.69
Tangible book value per share
4.945.574.884.283.69
Share holders equity per share
4.965.584.894.293.69
Interest debt per share
0.03-0.04-0.0600
Market cap
1.67B1.2B1.01B1.02B698.91M
Enterprise value
1.5B1B819.28M856.33M556.56M
P/E ratio
-21.84-17.37-11.63-9.71-6.81
Price to sales ratio
0-669.16K000
POCF ratio
-77.72-56.5-75.95-51.43-26.34
PFCF ratio
-73.76-57.4-73.96-51.45-26.32
P/B Ratio
8.435.294.935.714.51
PTB ratio
8.435.294.935.714.51
EV to sales
0-557.57K000
Enterprise value over EBITDA
-70.29-47.94-30.9-29.76-19.96
EV to operating cash flow
-69.62-47.07-61.81-42.98-20.98
EV to free cash flow
-66.08-47.83-60.19-42.99-20.96
Earnings yield
-0.01-0.01-0.02-0.03-0.04
Free cash flow yield
-0.01-0.02-0.01-0.02-0.04
Debt to equity
00000
Debt to assets
00000
Net debt to EBITDA
8.189.597.075.855.11
Current ratio
22.0629.9114.029.758.62
Interest coverage
-24.3111.6110.2200
Income quality
1.061.110.550.761.03
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0-1.83K000
Research and developement to revenue
0-9.81K000
Intangibles to total assets
00000
Capex to operating cash flow
0.05-0.020.0300
Capex to revenue
0-186.11000
Capex to depreciation
-3.850.86-0.910.02-0.06
Stock based compensation to revenue
0-342.22000
Graham number
7.317.317.557.817.12
ROIC
-0.1-0.08-0.12-0.14-0.16
Return on tangible assets
-0.09-0.07-0.1-0.13-0.15
Graham Net
4.154.754.153.612.98
Working capital
174.96M204.16M181.09M156.64M132.77M
Tangible asset value
197.98M226.92M203.5M178.97M154.85M
Net current asset value
174.71M203.93M180.89M156.64M132.77M
Invested capital
00000
Average receivables
000664K1.31M
Average payables
4.15M3.78M6.13M9.29M9.92M
Average inventory
000-664K-1.31M
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.1-0.08-0.11-0.15-0.17
Capex per share
-0.030.01-0.0100

SAVA Frequently Asked Questions

What is Cassava Sciences, Inc. stock symbol ?

Cassava Sciences, Inc. is a US stock , located in Austin of Tx and trading under the symbol SAVA

What is Cassava Sciences, Inc. stock quote today ?

Cassava Sciences, Inc. stock price is $22.49 today.

Is Cassava Sciences, Inc. stock public?

Yes, Cassava Sciences, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated Stocks